Authors
Latest:
Dr. Ferris on the CheckMate-041 Trial For Head and Neck CancerRobert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the significance of the CheckMate-041 trial for patients with head and neck cancer.
Latest:
Dr. Figlin on Advice for Oncologists Treating RCCRobert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides advice to community oncologists who are treating patients with renal cell carcinoma.
Latest:
Navigating Breast Cancer Survivorship: Sustaining the Good NewsForty years after the declaration of war on cancer, one of the most profound shifts in cancer care today is a new focus on treating those living beyond cancer, as well as those living with cancer.
Latest:
Dr. Maki on the Utility of IDH1/2 Inhibitors in ChondrosarcomaRobert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.
Latest:
Dr. Uzzo on Biomarker Development for RCCRobert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).
Latest:
Dr Uzzo on a Biomarker Analysis of the IMmotion010 Trial in RCCRobert Uzzo, MD, MBA, FACS, discusses a biomarker analysis of the IMmotion010 trial in patients with renal cell carcinoma.
Latest:
Dr. Andtbacka on Optimal Use of T-VEC in MelanomaRobert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the optimal use of talimogene laherparepvec (T-VEC) in patients with melanoma.
Latest:
Dr. Weiss on PPAR-Alpha as a Target in Kidney CancerRobert H. Weiss, MD, from the UC Davis Comprehensive Cancer Center, discusses peroxisome PPAR-alpha as a possible new treatment target for patients with renal cell carcinoma.
Latest:
Staging System for HPV-Related Oropharynx Cancer Paves Way for ChangeA new staging system for head and neck cancers recognizes that patients with oropharyngeal malignancies associated with the human papillomavirus often have an excellent prognosis, but efforts to deintensify therapy for this population based on a fresh understanding of favorable risk factors may be premature.
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell HistiocytosisIntensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Latest:
Dr. Cerfolio on the Importance of Specialized Care in Lung CancerRobert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the importance of specialized care in lung cancer and sheds light on the current outlook of the disease.
Latest:
Dr. Cerfolio on Minimally Invasive Surgery in NSCLCRobert J. Cerfolio, MD, MBA, director, Lung Cancer Center, chief, clinical thoracic surgery, discusses the impact of minimally invasive surgery in the management of non–small cell lung cancer.
Latest:
Dr. Kreitman on Ongoing Research With Moxetumomab Pasudotox in Hairy Cell LeukemiaRobert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses ongoing research with moxetumomab pasudotox-tdfk (Lumoxiti) in patients with hairy cell leukemia (HCL).
Latest:
Covering Your Assets: Tailoring Your Asset Protection Plan to Your Career StageThe type of asset protection planning you need depends on where you are in your career.
Latest:
Gimme Shelter: Are Financial Safe Havens Truly Safe Anymore?The largest US financial institutions are on government life support.
Latest:
Future Perspectives in the Treatment of Advanced RCCOncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.
Latest:
Robert Korngold on Advances in Bone Marrow TransplantRobert Korngold, PhD, John Theurer Cancer Center looks back on the advances we've made so far in bone marrow transplant.
Latest:
Dr. Coleman on the FDA Approval of Tisotumab Vedotin in Recurrent or Metastatic Cervical CancerRobert L. Coleman, MD, FACOG, FACS, discusses the FDA approval of tisotumab vedotin in recurrent or metastatic cervical cancer.
Latest:
Future Outlook of Advanced Ovarian Cancer TreatmentComprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.
